Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease

References

• Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009; 5:648–652.
   PubMed Web of Science ®Google Scholar
• Alballa S, Fritzler M, Davis P. A case of drug induced lupus due to carbamazepine. J Rheumatol. 1987; 14:599–600.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004; 85:277–285.
   PubMedGoogle Scholar
• Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000; 6:1167–1175.
   PubMed Web of Science ®Google Scholar
• Biesecker G, Noble B, Andres GA, Koffler D. Immunopathogenesis of Heymann's nephritis. Clin Immunol Immunopathol. 1984; 33:333–338.
   PubMedGoogle Scholar
• Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of nephritic syndrome in rats by Freund's adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959; 100:660–664.
   PubMed Web of Science ®Google Scholar
• Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009; 18:1217–1225.
   PubMed Web of Science ®Google Scholar
• Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity–friends or foes?. Trends Immunol. 2009; 30:409–414.
   PubMed Web of Science ®Google Scholar
• Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005; 38:235–245.
   PubMed Web of Science ®Google Scholar
• Naito T, Kawamura T, Bannai M, Kosaka T, Kameyama H, Shimamura K, Hoshi O, Ushiki T, Hatakeyama K, Abo T. Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol. 2002; 129:397–404.
   PubMed Web of Science ®Google Scholar
• Weir DM, Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology. 1967; 13:373–380.
   PubMedGoogle Scholar
• Weir DM, Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum. 1969; 12:254–260.
   PubMedGoogle Scholar
• Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med. 1996; 100 299–8.
   PubMedGoogle Scholar
• Chen M, von Mikecz A. Proteasomal processing of nuclear autoantigens in systemic autoimmunity. Autoimmun Rev. 2005; 4:117–122.
   PubMedGoogle Scholar
• Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev. 2008; 7:626–630.
   PubMed Web of Science ®Google Scholar
• Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10–26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev. 2007; 6:261–266.
   PubMedGoogle Scholar
• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg. 2002; 104:182–191.
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Thomas SL, Somers EC, Smeeth L, Kim J, Evans S, Hall AJ. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol. 2010; 70:588–596.
   PubMedGoogle Scholar
• Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, Sherer Y. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases–2008. Isr Med Assoc J. 2008; 10:8–12.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Blank M, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Levy Y, Orbach H, Pordeus V, Ram M, Sherer Y, Toubi E, Tomer Y. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases—2008. Isr Med Assoc J. 2008; 10:3–7.
   PubMedGoogle Scholar
• Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005; 38:473–485.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. 2008. An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In: Petrelli C. editors. New research on autoantibodies. Hauppauge NY: Nova Science Publishers, Inc.151–172.
   Google Scholar
• Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005; 26:425–432.
   PubMedGoogle Scholar
• Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005; 38:259–264.
   PubMed Web of Science ®Google Scholar
• Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol. 2005; 35:252–260.
   PubMed Web of Science ®Google Scholar
• Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004; 37:95–102.
   PubMed Web of Science ®Google Scholar
• Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens?. Environ Health Perspect. 1997; 105:1172–1174.
   PubMedGoogle Scholar
• Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases. Scand J Rheumatol. 2003; 32:2–11.
   PubMed Web of Science ®Google Scholar
• Ebringer A. 2003. Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali M. editors. Frontiers in Autoimmunity: fundamental aspects and clinical perspectives. Amsterdam Netherlands: IOS Press79–99.
   Google Scholar
• Ebringer A, Hughes L, Rashid T, Wilson C. Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol. 2005; 62:33–36.
   PubMedGoogle Scholar
• Ebringer A, Rashid T. Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed). 2009; 1:577–586.
   PubMedGoogle Scholar
• Mendrick DL, Noble B, Brentjens JR, Andres GA. Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int. 1980; 18:328–343.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM, Lafreniere R. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol. 2004; 85:201–212.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol. 2006; 13:17–24.
   PubMedGoogle Scholar
• Salant DJ, Cybulsky AV. Experimental glomerulonephritis. Methods Enzymol. 1988; 162:421–461.
   PubMedGoogle Scholar
• Stenglein B, Thoenes GH, Gunther E. Genetically controlled autologous immune complex glomerulonephritis in rats. J Immunol. 1975; 115:895–897.
   PubMedGoogle Scholar
• Barabas AZ, Lannigan R. Auto-immune nephritis in rats. J Pathol. 1969; 97:537–543.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003; 84:245–258.
   PubMedGoogle Scholar
• Edgington TS, Glassock RJ, Watson JI, Dixon FJ. Characterization and isolation of specific renal tubular epithelial antigens. J Immunol. 1967; 99:1199–1210.
   PubMedGoogle Scholar
• Edgington TS, Glassock RJ, Dixon FJ. Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med. 1968; 127:555–572.
   PubMed Web of Science ®Google Scholar
• Kamata K, Baird LG, Erikson ME, Collins AB, McCluskey RT. Characterization of antigens and antibody specificities involved in Heymann nephritis. J Immunol. 1985; 135:2400–2408.
   PubMedGoogle Scholar
• Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A. 1982; 79:5557–5581.
   PubMed Web of Science ®Google Scholar
• Naruse T, Fukasawa T, Miyakawa Y. Laboratory model of membranous glomerulonephritis in rats induced by pronase-digested homologous renal tubular epithelial antigen. Lab Invest. 1975; 33:141–146.
   PubMedGoogle Scholar
• Natori Y, Hayakawa I, Shibata S. Passive Heymann nephritis with acute and severe proteinuria induced by heterologous antibody against renal tubular brush border glycoprotein gp108. Lab Invest. 1986; 55:63–70.
   PubMedGoogle Scholar
• Singh AK, Makker SP. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology. 1986; 57:467–472.
   PubMedGoogle Scholar
• Tsukada Y, Ono K, Maezawa A, Yano S, Naruse T. A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border–studies with a monoclonal antibody against pronase-digested tubular antigen. Clin Exp Immunol. 1994; 96:303–310.
   PubMedGoogle Scholar
• Challice J, Barabas AZ, Cornish J, Bruce JW, Lannigan R. Passive Heymann nephritis in pre- and post-natal rats. Br J Exp Pathol. 1986; 67:915–924.
   PubMedGoogle Scholar
• Cornish J, Barabas AZ, Lannigan R. Modified immunofluorescent antibody test: demonstration of nephritogenic antigen in glomeruli of rats. Diagn Immunol. 1984; 2:133–136.
   PubMedGoogle Scholar
• Edgington TS, Glassock RJ, Dixon FJ. Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science. 1967; 155:1432–1434.
   PubMedGoogle Scholar
• Raychowdhury R, Zheng G, Brown D, McCluskey RT. Induction of Heymann nephritis with a gp330/megalin fusion protein. Am J Pathol. 1996; 148:1613–1623.
   PubMedGoogle Scholar
• Barabas AZ, Nagi AH, Lannigan R. Induction of experimental autologous immune-complex glomerulonephritis by eluted gamma-globulin. Int Urol Nephrol. 1971; 3:283–288.
   PubMedGoogle Scholar
• Couser WG, Steinmuller DR, Stilmant MM, Salant DJ, Lowenstein LM. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest. 1978; 62:1275–1287.
   PubMed Web of Science ®Google Scholar
• Makker SP, Moorthy B. In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest. 1981; 44:1–5.
   PubMedGoogle Scholar
• Sugisaki T, Klassen J, Andres GA, Milgrom F, McCluskey RT. Passive transfer of Heymann nephritis with serum. Kidney Int. 1973; 3:66–73.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int. 2006; 56:516–529.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004; 85:321–334.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Application of the modified vaccination technique for the prevention and cure of chronic ailments. Asian Pac J Trop Med. 2010; 3:160–166.
   Google Scholar
• Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev. 2008; 8:1–4.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Stenglein B, Thoenes GH, Gunther E. Genetic control of susceptibility to autologous immune complex glomerulonephritis in inbred rat strains. Clin Exp Immunol. 1978; 33:88–94.
   PubMedGoogle Scholar
• Alousi MA, Post RS, Heymann W. Experimental autoimmune nephrosis in rats. Morphogenesis of the glomerular lesion: immunohistochemical and electron microscopic studies. Am J Pathol. 1969; 54:47–71.
   PubMedGoogle Scholar
• Glassock RJ, Edgington TS, Watson JI, Dixon FJ. Autologous immune complex nephritis induced with renal tubular antigen. II. The pathogenetic mechanism. J Exp Med. 1968; 127:573–588.
   PubMedGoogle Scholar
• Kerjaschki D, Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983; 157:667–686.
   PubMed Web of Science ®Google Scholar
• Makker SP. Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol. 1993; 151:6500–6508.
   PubMedGoogle Scholar
• Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB. Specific uptake of Heymann's nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest. 1982; 46:450–453.
   PubMedGoogle Scholar
• Neale TJ, Wilson CB. Glomerular antigens in Heymann's nephritis: reactivity of eluted and circulating antibody. J Immunol. 1982; 128:323–330.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006; 56:181–190.
   PubMedGoogle Scholar
• Abrass CK, McVay J, Glassock RJ. Evaluation of homologous and isologous passive Heymann nephritis: influence on endogenous antibody production. J Immunol. 1983; 130:195–202.
   PubMedGoogle Scholar
• Singh AK, Schwartz MM. Circulatory antigen of Heymann nephritis. II. Isolation of a 70,000 MW antigen from normal rat serum which cross-reacts with Heymann nephritis antigen. Immunology. 1986; 59:451–458.
   PubMedGoogle Scholar
• Makker SP, Makker DM. A simple technique for detecting the antigen of Heymann nephritis in glomeruli by immunofluorescence. Clin Exp Immunol. 1986; 64:615–622.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Weir DM, Lafreniere R. 2011. The primary target antigenic site in Heymann nephritis is the renal proximal convoluted tubules' brush border associated zone of cells. In: Petrov M. editors. Autoimmune Disorders: Symptoms, Diagnosis and Treatment. Hauppauge NY: Nova Science Publishers, Inc.281–292.
   Google Scholar
• Batsford SR, Weghaupt R, Takamiya H, Vogt A. Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron. 1985; 41:146–151.
   PubMedGoogle Scholar
• Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest. 1982; 47:177–184.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. 2008. Pathogenic and nonpathogenic autoimmune events – the good and/or the bad?. In: Dubois Q. editors. Autoantibodies research progress. Hauppauge NY: Nova Science Publishers, Inc.9–18.
   Google Scholar
• Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005; 38:259–264.
   PubMed Web of Science ®Google Scholar
• Wermeling F, Karlsson MC, McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun Rev. 2009; 9:49–52.
   PubMedGoogle Scholar
• Noble B, Van Liew JB, Brentjens JR, Andres GA. Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest. 1982; 47:427–436.
   PubMedGoogle Scholar
• Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med. 1998; 188:2313–2320.
   PubMed Web of Science ®Google Scholar
• Pereira WO, Amarante-Mendes GP. Apoptosis: a programme of cell death or cell disposal?. Scand J Immunol. 2011; 73:401–407.
   PubMed Web of Science ®Google Scholar
• Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US, Herrmann M. Clearance deficiency—a potential link between infections and autoimmunity. Autoimmun Rev. 2008; 8:5–8.
   PubMed Web of Science ®Google Scholar
• Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995; 25:862–875.
   PubMed Web of Science ®Google Scholar
• Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004; 44:385–401.
   PubMed Web of Science ®Google Scholar
• Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009; 5:433–441.
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005; 4:526–531.
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010; 237:264–283.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005; 435:612–619.
   PubMed Web of Science ®Google Scholar
• Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009; 42:553–560.
   PubMed Web of Science ®Google Scholar
• Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R. Intravenous immunoglobulins—understanding properties and mechanisms. Clin Exp Immunol. 2009; 158 Suppl 1: 2–13.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)–beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009; 158 Suppl 1: 23–33.
   PubMedGoogle Scholar
• Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002; 107:387–393.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. BioProcess J. 2007; 6:12–18.
   Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs. 2008; 11:111–115.
   PubMedGoogle Scholar
• Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, Lafreniere R. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci. 2009; 14:3892–3898.
   Google Scholar
• Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev. 2009; 8:552–557.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scandinav J Immunol. 2010; 71:125–133.
   PubMedGoogle Scholar
• Blank M, Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun. 2007; 28:62–68.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 2000; 27:587–597.
   PubMedGoogle Scholar
• Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol. 1995; 155:925–937.
   PubMed Web of Science ®Google Scholar
• Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009; 158:1–9.
   PubMed Web of Science ®Google Scholar
• Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol. 1966; 1:433–442.
   PubMedGoogle Scholar
• Pinckard RN, Weir DM. Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol. 1966; 1:33–43.
   PubMedGoogle Scholar
• Weir DM. The immune response after tissue injury. Pathol Eur. 1966; 1:108–118.
   PubMedGoogle Scholar
• Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S. Formation of immune deposits and disease. Lab Invest. 1986; 55:510–520.
   PubMed Web of Science ®Google Scholar
• Kerjaschki D. Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig. 1993; 71:817–821.
   PubMedGoogle Scholar
• Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Safety. 2011; 34:117–123.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Cole CD, Weir DM, Lafreniere R. 2011. Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In: Petrov M. editors. Autoimmune disorders: symptoms, diagnosis and treatment. Hauppauge NY: Nova Science Publishers, Inc.35–66.
   Google Scholar
• Barabas AZ, Cole CD, Lafreniere R, Weir DM. 2012. Implicated autoantibodies in a kidney disease. In: Jenkins GE, Hall JI. editors. Autoantibodies: detection, pathogenicity and health implications. Hauppauge NY: Nova Science Publishers, Inc. In press.
   Google Scholar
• Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991; 12:154–159.
   PubMedGoogle Scholar
• Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995; 7:812–818.
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol. 2006; 17:1772–1774.
   PubMedGoogle Scholar
• Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens. 2006; 15:258–263.
   PubMedGoogle Scholar
• Pereira WO, Amarante-Mendes GP. Apoptosis: a program of cell death or cell disposal?. Scand J Immunol. 2011; 73:401–407.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010; 236:125–138.
   PubMed Web of Science ®Google Scholar
• Chu VT, Beller A, Nguyen TT, Steinhauser G, Berek C. The long-term survival of plasma cells. Scand J Immunol. 2011; 73:508–511.
   PubMedGoogle Scholar
• Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol. 2002; 14:517–521.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, Hoyer BF. Memory B and memory plasma cells. Immunol Rev. 2010; 237:117–139.
   PubMed Web of Science ®Google Scholar
• Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005; 4:565–570.
   PubMedGoogle Scholar
• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci. 2007; 1110:619–629.
   PubMed Web of Science ®Google Scholar